NDA 050810 · Thea Pharma
Azasite
Azithromycin · Ophthalmic
Last checked: Nov 19, 2026Latest source record: Jul 25, 2024 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2007
Apr 27, 2007
Approved uses
1
Original approval plus efficacy supplements
Registered trials
627
181 Phase 3, 43 recruiting
FAERS reports
1,475
351 serious, 25 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jul 25, 2024.
AzaSite ® is indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G Efficacy for this organism was studied in fewer than 10 infections. Haemophilus influenzae Staphylococcus aureus Streptococcus mitis group Streptococcus pneumoniae AzaSite is a macrolide antimicrobial indicated for the treatment of bacterial conjunctivitis caused by susceptible isolates of the following microorganisms: CDC coryneform group G, Haemophilus influenzae, Staphylococcus aureus, Streptococcus mitis group, and Streptococcus pneumoniae. ( 1 )
Mechanism: Azithromycin is a macrolide antibiotic [see Clinical Pharmacology (12.4) ] .
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
1 products under this application
- AZASITE · AZITHROMYCIN 1% · SOLUTION/DROPS, OPHTHALMIC · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Azithromycin" as an intervention, any sponsor and status, largest first.
- Azithromycin for Child Survival in Niger IIPivotal-lookingRecruiting
University of California, San FranciscoAcademic, hospital or other
NCT06358872 · 3,300,000 participants (planned) · Start Apr 29, 2024 · Primary completion Apr 29, 2028
Drug: Azithromycin for Oral Suspension · For: Mortality; Antimicrobial Resistance
Sites: Niamey, Niger
- Azithromycin for Child Survival in Niger: Mortality and Resistance TrialPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT04224987 · 864,493 participants · Start Nov 24, 2020 · Primary completion Jul 31, 2024
Drug: Azithromycin · For: Mortality; Resistance Bacterial; Child, Only
Sites: Niamey, Niger
FHI 360Academic, hospital or other
NCT05016895 · 767,535 participants · Start Aug 27, 2021 · Primary completion Jun 30, 2024
Drug: Single-dose azithromycin · For: Child Mortality
Sites: Abidjan, Côte d’Ivoire
- Infant Mortality Reduction by the Mass Administration of AzithromycinPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT04716712 · 694,400 participants (planned) · Start Oct 4, 2021 · Primary completion Jan 30, 2025
Drug: Azithromycin; Placebo · For: Child Mortality
Sites: San Francisco, California; Nouna, Burkina Faso; Ouagadougou, Burkina Faso
- Kebele Elimination of Trachoma for Ocular HealthPivotal-lookingActive, not recruiting
University of California, San FranciscoAcademic, hospital or other
NCT03335072 · 320,000 participants (planned) · Start Feb 7, 2022 · Primary completion Mar 1, 2027
Drug: Azithromycin · For: Trachoma
Sites: San Francisco, California; Bahir Dar, Ethiopia
- Mortality Reduction After Oral Azithromycin: Mortality StudyPivotal-lookingCompleted
University of California, San FranciscoAcademic, hospital or other
NCT02047981 · 190,238 participants · Start Dec 2014 · Primary completion Sep 2018
Drug: Azithromycin; Placebo · For: Childhood Mortality
Sites: San Francisco, California; Baltimore, Maryland; Blantyre, Malawi · 6 sites in all
- Azithromycin for Child Survival in Niger: Programmatic Trial (AVENIR)Pivotal-lookingTerminated
University of California, San FranciscoAcademic, hospital or other
NCT05288023 · 169,707 participants · Start Dec 1, 2022 · Primary completion Jan 15, 2024
Drug: Azithromycin for Oral Suspension · For: Resistance Bacterial; Morality; Child Health and 1 more
Sites: San Francisco, California
- Effects of Mass Drug Administration of Azithromycin on Mortality and Other Outcomes Among 1-11 Month Old Infants in MaliPivotal-lookingCompleted
Tampere UniversityAcademic, hospital or other
NCT04424511 · 149,201 participants · Start Oct 15, 2020 · Primary completion Dec 31, 2024
Drug: Placebo; Azithromycin · For: Mortality
Sites: Bamako, Mali
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- no adverse event421
- drug dose omission329
- product quality issue276
- inappropriate schedule of drug administration211
- eye irritation195
- product packaging quantity issue146
- off label use143
- drug ineffective132
- eye pain105
- eye pruritus105
- dyspnoea102
- lacrimation increased91
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2007 | 3 |
| 2008 | 16 |
| 2009 | 12 |
| 2010 | 14 |
| 2011 | 15 |
| 2012 | 201 |
| 2013 | 481 |
| 2014 | 43 |
| 2015 | 34 |
| 2016 | 64 |
| 2017 | 36 |
| 2018 | 39 |
| 2019 | 72 |
| 2020 | 118 |
| 2021 | 73 |
| 2022 | 65 |
| 2023 | 67 |
| 2024 | 39 |
| 2025 | 38 |
| 2026 | 45 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Azasite (Azithromycin)
2024 spending
$1.6M
Beneficiaries
3,244
5,084 claims
Per beneficiary
$485
$99.61 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $0 |
| 2021 | $0 |
| 2022 | $0 |
| 2023 | $1,296,942 |
| 2024 | $1,574,632 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Azithromycin for prevention of exacerbations of COPD.
Albert RK, Connett J, Bailey WC, et al. · N Engl J Med 2011 · Multicenter Study, Randomized Controlled Trial
- Effect of hydroxychloroquine with or without azithromycin on the mortality of coronavirus disease 2019 (COVID-19) patients: a systematic review and meta-analysis.
Fiolet T, Guihur A, Rebeaud ME, et al. · Clin Microbiol Infect 2021 · Meta-Analysis, Systematic Review
- Azithromycin for Poorly Controlled Asthma in Children: A Randomized Controlled Trial.
Ghimire JJ, Jat KR, Sankar J, et al. · Chest 2022 · Randomized Controlled Trial
- Systematic review and meta-analysis of treating meibomian gland dysfunction with azithromycin.
Tao T, Tao L · Eye (Lond) 2020 · Meta-Analysis, Systematic Review
- Azithromycin to Reduce Mortality - An Adaptive Cluster-Randomized Trial.
O'Brien KS, Arzika AM, Amza A, et al. · N Engl J Med 2024 · Adaptive Clinical Trial, Randomized Controlled Trial
- Efficacy and safety of azithromycin maintenance therapy in primary ciliary dyskinesia (BESTCILIA): a multicentre, double-blind, randomised, placebo-controlled phase 3 trial.
Kobbernagel HE, Buchvald FF, Haarman EG, et al. · Lancet Respir Med 2020 · Clinical Trial, Phase III, Multicenter Study
Sponsor: Thea Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.